Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase

Molecular Therapy

Volumn 20, Issue 5, 2012, Pages 1002-1013

  Neschadim, Anton ^a   Wang, James C M ^a   Sato, Takeya ^b   Fowler, Daniel H ^c   Lavie, Arnon ^d   Medin, Jeffrey A ^a,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b TOHOKU UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BROMOVINYL DEOXYURIDINE; DEOXYCYTIDINE KINASE; DEOXYURIDINE; LENTIVIRUS VECTOR; THYMIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CANCER CHEMOTHERAPY; CELL BASED GENE THERAPY; CELL FATE CONTROL GENE THERAPY; CELL STRAIN MOLT 4; CELL STRAIN U87MG; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; ENZYME ACTIVATION; GENE DIRECTED ENZYME PRODRUG THERAPY; GENETIC ENGINEERING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA; LEUKEMIA CELL LINE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TARGET CELL;

EID: 84862829497     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.298     Document Type: Article

References (51)

1. Rezvani, AR and Storb, RF (2008). Separation of graft-vs.-tumor effects from graftvs.-host disease in allogeneic hematopoietic cell transplantation. J Autoimmun 30: 172-179.
2. Fraser, CJ, Hirsch, BA, Dayton, V, Creer, MH, Neglia, JP, Wagner, JE et al. (2005). First report of donor cell-derived acute leukemia as a complication of umbilical cord blood transplantation. Blood 106: 4377-4380. (Pubitemid 41775951)
3. Amariglio, N, Hirshberg, A, Scheithauer, BW, Cohen, Y, Loewenthal, R, Trakhtenbrot, L et al. (2009). Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 6: e1000029.
4. Cooley, LD, Sears, DA, Udden, MM, Harrison, WR and Baker, KR (2000). Donor cell leukemia: report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol 63: 46-53. (Pubitemid 30023022)
5. Goring, DR and DuBow, MS (1985). A cytotoxic effect associated with 9-(1,3-dihydroxy-2-propoxymethyl)-guanine is observed during the selection for drug resistant human cells containing a single herpesvirus thymidine kinase gene. Biochem Biophys Res Commun 133: 195-201. (Pubitemid 16155345)
6. Verzeletti, S, Bonini, C, Marktel, S, Nobili, N, Ciceri, F, Traversari, C et al. (1998). Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum Gene Ther 9: 2243-2251. (Pubitemid 28498010)
7. Deschamps, M, Mercier-Lethondal, P, Certoux, JM, Henry, C, Lioure, B, Pagneux, C et al. (2007). Deletions within the HSV-tk transgene in long-lasting circulating genemodified T cells infused with a hematopoietic graft. Blood 110: 3842-3852. (Pubitemid 350248439)
8. Garin, MI, Garrett, E, Tiberghien, P, Apperley, JF, Chalmers, D, Melo, JV et al. (2001). Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97: 122-129. (Pubitemid 32061251)
9. Fehse, B, Ayuk, FA, Kröger, N, Fang, L, Kühlcke, K, Heinzelmann, M et al. (2004). Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells. Blood 104: 3408-3409. (Pubitemid 39507166)
10. Ardiani, A, Sanchez-Bonilla, M and Black, ME (2010). Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo. Cancer Gene Ther 17: 86-96.
11. Candice L, W, Django, S and Margaret E, B (2008). The role of herpes simplex virus-1 thymidine kinase alanine 168 in substrate specificity. Open Biochem J 2: 60-66.
12. Willmon, CL, Krabbenhoft, E and Black, ME (2006). A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing. Gene Ther 13: 1309-1312. (Pubitemid 44264085)
13. Tiberghien, P, Ferrand, C, Lioure, B, Milpied, N, Angonin, R, Deconinck, E et al. (2001). Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97: 63-72. (Pubitemid 32061243)
14. Bennour, E, Ferrand, C, Rémy-Martin, JP, Certoux, JM, Gorke, S, Qasim, W et al. (2008). Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance. Hum Gene Ther 19: 699-709. (Pubitemid 352009909)
15. Bonini, C and Bordignon, C (1997). Potential and limitations of HSV-TK-transduced donor peripheral blood lymphocytes after allo-BMT. Hematol Cell Ther 39: 273-274. (Pubitemid 27483741)
16. Riddell, SR, Elliott, M, Lewinsohn, DA, Gilbert, MJ, Wilson, L, Manley, SA et al. (1996). T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2: 216-223. (Pubitemid 26057556)
17. Berger, C, Flowers, ME, Warren, EH and Riddell, SR (2006). Analysis of transgenespecific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107: 2294-2302. (Pubitemid 43345547)
18. Noble, S and Faulds, D (1998). Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 56: 115-146. (Pubitemid 28340192)
19. Sato, T, Neschadim, A, Konrad, M, Fowler, DH, Lavie, A and Medin, JA (2007). Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther 15: 962-970. (Pubitemid 46621655)
20. Sabini, E, Hazra, S, Ort, S, Konrad, M and Lavie, A (2008). Structural basis for substrate promiscuity of dCK. J Mol Biol 378: 607-621.
21. Sabini, E, Hazra, S, Konrad, M, Burley, SK and Lavie, A (2007). Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase. Nucleic Acids Res 35: 186-192. (Pubitemid 46189843)
22. Sabini, E, Hazra, S, Konrad, M and Lavie, A (2007). Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L-and D-nucleosides. J Med Chem 50: 3004-3014. (Pubitemid 47001243)
23. Sabini, E, Ort, S, Monnerjahn, C, Konrad, M and Lavie, A (2003). Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 10: 513-519. (Pubitemid 36792901)
24. Hazra, S, Sabini, E, Ort, S, Konrad, M and Lavie, A (2009). Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase. Biochemistry 48: 1256-1263.
25. Hazra, S, Ort, S, Konrad, M and Lavie, A (2010). Structural and kinetic characterization of human deoxycytidine kinase variants able to phosphorylate 5-substituted deoxycytidine and thymidine analogues. Biochemistry 49: 6784-6790.
26. McSorley, T, Ort, S, Hazra, S, Lavie, A and Konrad, M (2008). Mimicking phosphorylation of Ser-74 on human deoxycytidine kinase selectively increases catalytic activity for dC and dC analogues. FEBS Lett 582: 720-724.
27. Hazra, S, Szewczak, A, Ort, S, Konrad, M and Lavie, A (2011). Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release. Biochemistry 50: 2870-2880.
28. Toy, G, Austin, WR, Liao, HI, Cheng, D, Singh, A, Campbell, DO et al. (2010). Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci USA 107: 5551-5556.
29. Likar, Y, Zurita, J, Dobrenkov, K, Shenker, L, Cai, S, Neschadim, A et al. (2010). A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine- based cytotoxic drugs. J Nucl Med 51: 1395-1403.
30. Gallardo, HF, Tan, C and Sadelain, M (1997). The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Ther 4: 1115-1119. (Pubitemid 27469943)
31. Lackey, DB, Groziak, MP, Sergeeva, M, Beryt, M, Boyer, C, Stroud, RM et al. (2001). Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem Pharmacol 61: 179-189. (Pubitemid 32121782)
32. Takezawa, K, Okamoto, I, Tsukioka, S, Uchida, J, Kiniwa, M, Fukuoka, M et al. (2010). Identification of thymidylate synthase as a potential therapeutic target for lung cancer. Br J Cancer 103: 354-361.
33. Neschadim, A, McCart, JA, Keating, A and Medin, JA (2007). A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. Biol Blood Marrow Transplant 13: 1407-1416. (Pubitemid 350091394)
34. Lai, CL, Lim, SG, Brown, NA, Zhou, XJ, Lloyd, DM, Lee, YM et al. (2004). A dosefinding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40: 719-726. (Pubitemid 39265595)
35. de Clercq, E, Degreef, H, Wildiers, J, de Jonge, G, Drochmans, A, Descamps, J et al. (1980). Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster. Br Med J 281: 1178. (Pubitemid 10024698)
36. Benoit, Y, Laureys, G, Delbeke, MJ and De Clercq, E (1985). Oral BVDU treatment of varicella and zoster in children with cancer. Eur J Pediatr 143: 198-202. (Pubitemid 15130701)
37. Baba, M, Shigeta, S and De Clercq, E (1987). Serum and urine concentrations of oral bromovinyldeoxyuridine in humans as monitored by a bioassay system based on varicella-zoster virus focus inhibition. J Med Virol 22: 17-23. (Pubitemid 17077595)
38. Balzarini, J, De Clercq, E, Verbruggen, A, Ayusawa, D, Shimizu, K and Seno, T (1987). Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene. Mol Pharmacol 32: 410-416. (Pubitemid 18007297)
39. Bridges, EG, Selden, JR and Luo, S (2008). Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother 52: 2521-2528. (Pubitemid 351915684)
40. Focher, F, Maga, G, Bendiscioli, A, Capobianco, M, Colonna, F, Garbesi, A et al. (1995). Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D-and L-thymidine 5'-triphosphate as substrate. Nucleic Acids Res 23: 2840-2847.
41. Smal, C, Vertommen, D, Bertrand, L, Rider, MH, van den Neste, E and Bontemps, F (2006). Identification of phosphorylation sites on human deoxycytidine kinase after overexpression in eucaryotic cells. Nucleosides Nucleotides Nucleic Acids 25: 1141-1146. (Pubitemid 44651862)
42. Frank, O, Rudolph, C, Heberlein, C, von Neuhoff, N, Schröck, E, Schambach, A et al. (2004). Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood 104: 3543-3549. (Pubitemid 39564425)
43. Grignet-Debrus, C, Cool, V, Baudson, N, Degrève, B, Balzarini, J, De Leval, L et al. (2000). Comparative in vitro and in vivo cytotoxic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and its arabinosyl derivative, (E)-5-(2-bromovinyl)-1-beta-D-arabinofuranosyluracil (BVaraU), against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase. Cancer Gene Ther 7: 215-223. (Pubitemid 30194555)
44. De Clercq, E (1986). Potential of bromovinyldeoxyuridine in anticancer chemotherapy. Anticancer Res 6: 549-556. (Pubitemid 16032793)
45. Di Stasi, A, Tey, SK, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
46. Straathof, KC, Pulè, MA, Yotnda, P, Dotti, G, Vanin, EF, Brenner, MK et al. (2005). An inducible caspase 9 safety switch for T-cell therapy. Blood 105: 4247-4254. (Pubitemid 40720769)
47. Tey, SK, Dotti, G, Rooney, CM, Heslop, HE and Brenner, MK (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13: 913-924. (Pubitemid 47055386)
48. Yoshimitsu, M, Sato, T, Tao, K, Walia, JS, Rasaiah, VI, Sleep, GT et al. (2004). Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA 101: 16909-16914. (Pubitemid 39601337)
49. Walia, JS, Neschadim, A, Lopez-Perez, O, Alayoubi, A, Fan, X, Carpentier, S et al. (2011). Autologous transplantation of lentivector/acid ceramidase-transduced hematopoietic cells in nonhuman primates. Hum Gene Ther 22: 679-687.
50. Ayisi, NK, De Clercq, E, Wall, RA, Hughes, H and Sacks, SL (1984). Metabolic fate of (E)-5-(2-bromovinyl)-2'-deoxyuridine in herpes simplex virus-and mock-infected cells. Antimicrob Agents Chemother 26: 762-765. (Pubitemid 15211677)
51. McKenzie, JL, Gan, OI, Doedens, M and Dick, JE (2005). Human short-term repopulating stem cells are efficiently detected following intrafemoral transplantation into NOD/SCID recipients depleted of CD122+ cells. Blood 106: 1259-1261. (Pubitemid 41129588)